Hologic completes sale of Cynosure medical aesthetics business

Hologic (NSDQ:HOLX) announced today that it has completed the previously announced $205 million sale of its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice.
Minus closing adjustments, Hologic initially estimates it will receive net cash proceeds of $142 million from the sale.
CEO Steve MacMillan previously said the sale would enable Hologic to better focus on its core business of early disease detection for women.
Original Article: (https://www.massdevice.com/hologic-completes-sale-of-cynosure-medical-aesthetics-business/)